US67022C2052 - ADR
EDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States...
On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab) for metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy. In this 12-patient cohort, most patients had received at least two prior lines of PD-1 inhibitor therapy. Nine out of twelve (75%) achieved disease control, including two patients who achieved Partial Resp
Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety Profile
Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses,...
NuTide:323 Study to be Discontinued Following Pre-Planned Initial Analysis and Recommendation from the Steering Committee NuTide:701 and NuTide:303...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips NuCana (NASDAQ:NCNA) just reported results for the second quarter of 2024.NuCan...
NCNA stock results show that NuCana beat analyst estimates for earnings per share the second quarter of 2024.
Key Data Readouts on Track for All Programs in 2024 Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, Aug. 15, 2024 (GLOBE NEWSWIRE) --...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips NuCana (NASDAQ:NCNA) just reported results for the first quarter of 2024.NuCana...
NCNA stock results show that NuCana beat analyst estimates for earnings per share the first quarter of 2024.
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled ...
EDINBURGH, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a...
NUC-7738 Reprograms Cancer Cell Lipid Metabolism to Make Tumors Less Aggressive and Promote Cancer Cell Death NUC-7738 Alters Ribosome Biogenesis and the...